Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | DRD4 | P21917 | 6/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 5/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274879 | 0.91 | JAK3 (0.47) | DRD2DRD4SCN9AROCK2HTR2A | |
| SCHEMBL13689489 | 0.84 | JAK3 (0.48) | DRD2DRD4HTR2AJAK1JAK2 | |
| SCHEMBL12402508 | 0.84 | PRKACA (0.45) | DRD2DRD4JAK1JAK2PARP1 | |
| SCHEMBL12402545 | 0.82 | HSP90AA1 (0.40) | JAK1JAK2JAK3MCHR1 | |
| SCHEMBL2275248 | 0.80 | JAK3 (0.50) | DRD2DRD4HTR2AJAK1JAK2 | |
| SCHEMBL12402511 | 0.78 | JAK3 (0.50) | DRD2DRD4HTR2AJAK1JAK2 | |
| SCHEMBL2275838 | 0.77 | JAK3 (0.48) | DRD2DRD4ROCK2JAK1JAK2 | |
| SCHEMBL2280391 | 0.76 | JAK3 (0.51) | ROCK2JAK1JAK2JAK3TYK2 | |
| SCHEMBL12402506 | 0.76 | HSP90AA1 (0.42) | JAK3MCHR1 | |
| SCHEMBL2277617 | 0.76 | JAK3 (0.49) | JAK1JAK2JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | DRD2 3196/4885DRD4 3704/4885SCN9A 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.